Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2006-03-17
Last Posted Date
2013-08-14
Lead Sponsor
University of California, San Francisco
Target Recruit Count
5
Registration Number
NCT00304018
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2006-03-13
Last Posted Date
2012-10-02
Lead Sponsor
University of California, San Francisco
Registration Number
NCT00301912
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2006-03-13
Last Posted Date
2017-10-12
Lead Sponsor
University of California, San Francisco
Target Recruit Count
7
Registration Number
NCT00301951
Locations
🇺🇸

UCSF Comprehensive Cancer Center, San Francisco, California, United States

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

First Posted Date
2006-03-13
Last Posted Date
2017-09-28
Lead Sponsor
University of California, San Francisco
Target Recruit Count
35
Registration Number
NCT00301834
Locations
🇺🇸

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

First Posted Date
2006-02-24
Last Posted Date
2012-10-04
Lead Sponsor
University of California, San Francisco
Target Recruit Count
25
Registration Number
NCT00296023
Locations
🇺🇸

Alta Bates Comprehensive Cancer Center, Berkeley, California, United States

🇺🇸

UCSF Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

First Posted Date
2006-02-24
Last Posted Date
2014-01-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
35
Registration Number
NCT00295997
Locations
🇺🇸

UCSF Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2006-02-13
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
43
Registration Number
NCT00290628
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

First Posted Date
2006-01-25
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
200
Registration Number
NCT00281879
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

First Posted Date
2006-01-25
Last Posted Date
2017-07-24
Lead Sponsor
German CLL Study Group
Target Recruit Count
100
Registration Number
NCT00281983
Locations
🇩🇪

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany

🇩🇪

University Hospital of Leipzig, Leipzig, Germany

🇩🇪

Klinikum der Universitaet Regensburg, Regensburg, Germany

and more 10 locations

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

First Posted Date
2005-12-15
Last Posted Date
2013-11-20
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
42
Registration Number
NCT00265889
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy